SCHEDULE: BlackRock Discloses 7% Stake in Dyne Therapeutics

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 7.0% of Dyne Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• BlackRock, Inc. has reported a beneficial ownership stake of 7.0% in Dyne Therapeutics, Inc.
• The filing, a Schedule 13G, indicates that BlackRock beneficially owns 11,489,504 shares.
• This ownership includes sole voting power over 11,273,443 shares and sole dispositive power over 11,489,504 shares.
• The filing was made on July 28, 2026, with the event date requiring the filing being June 30, 2026.
• BlackRock, Inc. is organized in Delaware and its principal business office is located at 50 Hudson Yards, New York, NY 10001.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine ownership disclosure by an institutional investor and does not provide new operational or financial information about the company.

Positives

• BlackRock's significant stake suggests confidence in Dyne Therapeutics' long-term prospects.
• The filing indicates a substantial investment by a major institutional investor.

Risks

• The filing does not contain specific risk factors related to Dyne Therapeutics' business operations or financial performance.

Future Outlook

The filing is a disclosure of ownership and does not contain forward-looking statements or guidance from Dyne Therapeutics.

Industry Context

StockSavvy.ai notes that significant stake disclosures by large asset managers like BlackRock often signal a belief in the target company's growth potential within its sector, in this case, biotechnology.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by BlackRock may be viewed positively, potentially indicating institutional confidence in the company's future.

Key Dates

Keywords

Dyne Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management